| Symbol | AKBA |
|---|---|
| Name | AKEBIA THERAPEUTICS, INC. |
| Sector | HEALTH CARE |
| Region | North America |
| Industry | Biotechnology: Pharmaceutical Preparations |
| Address | 245 FIRST STREET,SUITE 1100, CAMBRIDGE, Massachusetts, 02142, United States |
| Telephone | +1 617 871-2098 |
| Fax | — |
| — | |
| Website | https://www.akebia.com |
| Incorporation | UNDEFINED |
| Incorporated On | — |
| Employees | — |
| Fiscal Year | — |
| Public Since | — |
| Exchanges | NASDAQ |
| Auditor | — |
| Audit Status | NOT PROVIDED |
| Reporting Status | — |
| CIK | 0001517022 |
| Description | Akebia Therapeutics Inc is a biopharmaceutical company. It focuses on the development and commercialization of novel therapeutics to patients with kidney disease through hypoxia-inducible factor (HIF) biology. Its lead product candidate is Vadadustat, an oral therapy, which is used for the treatment of anemia related to chronic kidney disease in non-dialysis and dialysis patients. The company is also developing a HIF-based portfolio of product for the treatment of anemia. Geographically, all the business activity is functioned through the region of United States. Additional info from NASDAQ: |
2026-08-10 20:08
Butler John P. 🟡 adjusted position in 0 shares (1 derivative) of Akebia Therapeutics, Inc. (AKBA) at $0.63 Transaction Date: Aug 06, 2026 | Filing ID: 000004
Read more
2026-08-03 20:05
Akebia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Read more
2026-08-03 12:00
Akebia Therapeutics Announces Initiation of a Phase 2 Basket Trial to Study Ebribafusp, a Next-Generation Complement Inhibitor in Rare Kidney Diseases
Read more
2026-07-29 12:00
Akebia Therapeutics to Report Second Quarter 2026 Financial Results and Discuss Recent Business Highlights
Read more
2026-07-02 20:05
Akebia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Read more
2026-06-30 12:05
(99% Positive) AKEBIA THERAPEUTICS, INC. (AKBA) Announces Clinical Development Update
Read more
2026-06-30 00:38
📋 Ostrowski Erik (Officer) plans to sell 56K shares of Akebia Therapeutics, Inc. (at $1.11 each, total $62K) Filed: Jun 29, 2026 | ID: 000044
Read more
2026-06-22 20:24
Wolf Myles 🟢 acquired 89.3K shares (1 derivative) of Akebia Therapeutics, Inc. (AKBA) at $1.02 Transaction Date: Jun 17, 2026 | Filing ID: 000001
Read more
2026-06-22 20:23
Smith Cynthia 🟢 acquired 89.3K shares (1 derivative) of Akebia Therapeutics, Inc. (AKBA) at $1.02 Transaction Date: Jun 17, 2026 | Filing ID: 000003
Read more
2026-06-22 20:22
ROGERS MICHAEL W 🟢 acquired 89.3K shares (1 derivative) of Akebia Therapeutics, Inc. (AKBA) at $1.02 Transaction Date: Jun 17, 2026 | Filing ID: 000001
Read more| Trial ID | Title | Phase | Indication | Status | Start Date | Completion Date | Source |
|---|---|---|---|---|---|---|---|
| NCT06419205 | A Phase 2 Study to Evaluate the Safety, PD, PK, and Clinical Activity of ADX-09… | Phase2 | IgA Nephropathy | Recruiting | 2026-07-30 | 2028-02-01 | ClinicalTrials.gov |
| NCT07565701 | Safety and Efficacy of a Phased Transition From Epogen to Three Times Weekly Or… | Phase3 | Anemia Associated With Chronic Kidney Disease | Not_Yet_Recruiting | 2026-04-01 | 2027-06-01 | ClinicalTrials.gov |
| NCT07429006 | SAD and MAD Study of AKB-9090 in Healthy Adult Participants | Phase1 | Healthy Volunteers | Recruiting | 2026-03-16 | 2026-12-01 | ClinicalTrials.gov |
| NCT07268638 | A Study of Praliciguat in Participants With Focal Segmental Glomerulosclerosis … | Phase2 | Focal Segmental Glomerulosclerosis | Recruiting | 2025-12-03 | 2028-01-01 | ClinicalTrials.gov |
| NCT07086755 | Vadadustat for the Treatment of Nonintubated Acute Respiratory Distress Syndrom… | Phase2 | Nonintubated Acute Respiratory Distress Syndrome (ARDS) | Recruiting | 2025-10-23 | 2031-05-31 | ClinicalTrials.gov |
| NCT06901505 | To Evaluate the Efficacy of Three Times Weekly (TIW) Vadadustat Compared to Sta… | Phase3 | Anemia of Chronic Kidney Disease | Completed | 2025-07-24 | 2026-08-12 | ClinicalTrials.gov |
| NCT05082584 | Study to Evaluate the Safety and Efficacy of Oral Vadadustat in Pediatric Parti… | Phase3 | Anemia of Chronic Kidney Disease | Withdrawn | 2025-01-01 | 2026-10-01 | ClinicalTrials.gov |
| NCT05082571 | Study to Evaluate the Safety and Efficacy of Oral Vadadustat in Pediatric Parti… | Phase3 | Anemia of Chronic Kidney Disease | Withdrawn | 2025-01-01 | 2026-10-01 | ClinicalTrials.gov |
| NCT06520826 | Vafseo Outcomes In-Center Experience | Phase3 | Anemia of Chronic Kidney Disease | Active_Not_Recruiting | 2024-11-20 | 2026-06-30 | ClinicalTrials.gov |
| NCT05085275 | Ferric Citrate for the Prevention of Renal Failure in Adults With Advanced Chro… | Phase3 | Anemia, Iron Deficiency | Completed | 2022-03-30 | 2024-01-24 | ClinicalTrials.gov |
| NCT04922645 | Auryxia (Ferric Citrate) Therapy for In-Center and Home Dialysis Participants | Phase4 | Hyperphosphatemia | Completed | 2021-06-29 | 2022-09-15 | ClinicalTrials.gov |
| NCT04707768 | Study Evaluating the Efficacy and Safety of Dose Conversion From a Long-acting … | Phase3 | Anemia Associated With Chronic Kidney Disease (CKD) | Completed | 2021-06-18 | 2023-01-30 | ClinicalTrials.gov |
| NCT04478071 | Vadadustat for the Prevention and Treatment of Acute Respiratory Distress Syndr… | Phase2 | Acute Respiratory Distress Syndrome | Completed | 2020-08-22 | 2022-03-25 | ClinicalTrials.gov |
| NCT04299633 | Study in Healthy Adult Subjects to Assess the Effect of Phosphate Binders on th… | Phase1 | Healthy Volunteers | Completed | 2020-06-15 | 2020-09-28 | ClinicalTrials.gov |
| NCT04313153 | Trial Evaluating the Efficacy and Safety of Oral Vadadustat Once Daily (QD) and… | Phase3 | Anemia | Completed | 2020-05-27 | 2022-06-22 | ClinicalTrials.gov |
| NCT03992066 | Study to Evaluate the Pharmacokinetics, Pharmacodynamics, and Safety of Vadadus… | Phase1 | Anemia Associated With Chronic Kidney Disease | Completed | 2019-05-28 | 2020-07-15 | ClinicalTrials.gov |
| NCT03799627 | Study of Vadadustat in Hemodialysis Participants With Anemia Switching From Epo… | Phase2 | Anemia | Completed | 2019-01-31 | 2020-07-15 | ClinicalTrials.gov |
| NCT03789032 | Study to Evaluate the Effect of Rabeprazole on the Pharmacokinetics of Vadadust… | Phase1 | Drug Interaction Potentiation | Completed | 2018-10-03 | 2018-11-19 | ClinicalTrials.gov |
| NCT03657290 | A Study in Evaluating Bioequivalence of Test and Reference Vadadustat 450 MG an… | Phase1 | Healthy | Completed | 2018-08-03 | 2018-10-16 | ClinicalTrials.gov |
| NCT03801759 | Drug-Drug Interaction Study of Vadadustat With Digoxin, Adefovir and Furosemide | Phase1 | Drug Interaction Potentiation | Completed | 2018-07-20 | 2018-09-30 | ClinicalTrials.gov |
| NCT03801746 | Drug-Drug Interaction Study of Vadadustat With Cyclosporine, Probenecid and Rif… | Phase1 | Drug Interaction Potentiation | Completed | 2018-07-20 | 2018-08-15 | ClinicalTrials.gov |
| NCT03801733 | Drug-Drug Interaction Study of Vadadustat With Rosuvastatin, Sulfasalazine, Pra… | Phase1 | Drug Interaction Potentiation | Completed | 2018-06-17 | 2018-11-24 | ClinicalTrials.gov |
| NCT03799848 | A Single Dose Study of Oral Vadadustat in Subjects With Normal and Impaired Hep… | Phase1 | Hepatic Impairment | Completed | 2018-06-12 | 2018-10-18 | ClinicalTrials.gov |
| NCT03639155 | A Study in Evaluating Bioequivalence Between Test and Reference Formulations of… | Phase1 | Healthy | Completed | 2018-04-12 | 2018-05-23 | ClinicalTrials.gov |
| NCT03242967 | Study to Evaluate Three Times Per Week (TIW) Oral Dosing of Vadadustat for Anem… | Phase3 | Anemia | Withdrawn | 2017-08-01 | 2018-02-12 | ClinicalTrials.gov |
| NCT03140722 | Study to Evaluate Vadadustat for Anemia in Subjects With Dialysis-Dependent Chr… | Phase2 | Anemia | Terminated | 2017-05-02 | 2018-03-21 | ClinicalTrials.gov |
| NCT03054350 | Dose-Finding Study of Vadadustat in Japanese Subjects With Anemia Secondary to … | Phase2 | Anemia | Completed | 2016-12-01 | 2018-01-24 | ClinicalTrials.gov |
| NCT03054337 | Dose-Finding Study of Vadadustat in Japanese Subjects With Anemia Secondary to … | Phase2 | Anemia | Completed | 2016-10-01 | 2017-08-28 | ClinicalTrials.gov |
| NCT02892149 | Efficacy and Safety Study to Evaluate Vadadustat for the Maintenance Treatment … | Phase3 | Anemia | Completed | 2016-08-01 | 2020-03-30 | ClinicalTrials.gov |
| NCT02865850 | Efficacy and Safety Study to Evaluate Vadadustat for the Correction or Maintena… | Phase3 | Anemia | Completed | 2016-07-01 | 2020-03-30 | ClinicalTrials.gov |
| NCT02680574 | Efficacy and Safety Study to Evaluate Vadadustat for the Maintenance Treatment … | Phase3 | Anemia | Completed | 2016-02-01 | 2020-07-31 | ClinicalTrials.gov |
| NCT02648347 | Study to Evaluate Vadadustat for the Correction of Anemia in Participants With … | Phase3 | Anemia | Completed | 2015-12-01 | 2020-07-31 | ClinicalTrials.gov |
| NCT02502500 | Effect of AKB-6548 on the Pharmacokinetics of Celecoxib | Phase1 | Healthy Volunteers | Completed | 2015-07-01 | 2015-09-01 | ClinicalTrials.gov |
| NCT02412449 | Relative Bioavailability of Two Formulations of AKB-6548 and the Food Effect of… | Phase1 | Healthy | Completed | 2015-04-01 | 2015-04-01 | ClinicalTrials.gov |
| NCT02327546 | Effects of Ferrous Sulfate on the Pharmacokinetics of AKB-6548 | Phase1 | Healthy Volunteers | Completed | 2014-12-01 | 2015-02-01 | ClinicalTrials.gov |
| NCT02260193 | 16-Week Repeat Oral Dose Study of AKB-6548 for Anemia in Participants With End … | Phase2 | Anemia | Completed | 2014-09-10 | 2015-07-22 | ClinicalTrials.gov |
| NCT02062203 | Effect of AKB-6548 on Cardiac Repolarization Intervals in Healthy Volunteers | Phase1 | Healthy Volunteers | Completed | 2014-01-01 | 2014-04-01 | ClinicalTrials.gov |
| NCT01906489 | 20-Week Repeat Oral Dose Study of AKB-6548 in Participants With Chronic Kidney … | Phase2 | Anemia | Completed | 2013-07-23 | 2014-09-03 | ClinicalTrials.gov |
| NCT01381094 | 42-Day Repeat Oral Dose Study of AKB-6548 in Participants With Chronic Kidney D… | Phase2 | Anemia | Completed | 2011-06-15 | 2012-02-16 | ClinicalTrials.gov |
| NCT01235936 | Safety and Efficacy Study for AKB-6548 in Participants With Chronic Kidney Dise… | Phase2 | Anemia | Completed | 2010-10-21 | 2011-05-01 | ClinicalTrials.gov |
| NCT04707573 | Study to Assess the Safety and Pharmacokinetics of AKB-6548 in Participants Wit… | Phase2 | Chronic Kidney Disease | Completed | 2010-07-08 | 2010-09-24 | ClinicalTrials.gov |
Total clinical trials: 41
| Product Name | Type | Development Stage | Therapeutic Area | Study Status | Trial ID |
|---|---|---|---|---|---|
| Vadadustat | Other | Phase PHASE3 | Anemia of Chronic Kidney Disease | COMPLETED | NCT06901505 |
| Erythropoiesis-Stimulating Agent (ESA) | Other | Phase PHASE3 | Anemia of Chronic Kidney Disease | COMPLETED | NCT06901505 |
| Placebo | Other | Phase PHASE2 | Focal Segmental Glomerulosclerosis | RECRUITING | NCT07268638 |
| Praliciguat | Other | Phase PHASE2 | Focal Segmental Glomerulosclerosis | RECRUITING | NCT07268638 |
| Placebo | Other | Phase PHASE2 | Nonintubated Acute Respiratory Distress Syndrome (ARDS) | RECRUITING | NCT07086755 |
| Vadadustat 1200mg | Other | Phase PHASE2 | Nonintubated Acute Respiratory Distress Syndrome (ARDS) | RECRUITING | NCT07086755 |
| Vadadustat 900mg | Other | Phase PHASE2 | Nonintubated Acute Respiratory Distress Syndrome (ARDS) | RECRUITING | NCT07086755 |
| ADX-097 | Other | Phase PHASE2 | IgA Nephropathy | RECRUITING | NCT06419205 |
| ADX-097 | Other | Phase PHASE2 | IgA Nephropathy | NOT_YET_RECRUITING | NCT06419205 |
| Placebo | Other | Phase PHASE2 | Focal Segmental Glomerulosclerosis | RECRUITING | NCT07268638 |
| Praliciguat | Other | Phase PHASE2 | Focal Segmental Glomerulosclerosis | RECRUITING | NCT07268638 |
| Epoetin alga (Epogen)/vadadustat | Other | Phase PHASE3 | Anemia Associated With Chronic Kidney Disease | NOT_YET_RECRUITING | NCT07565701 |
| Epoetin alga (Epogen)/vadadustat | Other | Phase PHASE3 | Anemia Associated With Chronic Kidney Disease | NOT_YET_RECRUITING | NCT07565701 |
| Epoetin alga (Epogen)/vadadustat | Other | Phase PHASE3 | Anemia Associated With Chronic Kidney Disease | NOT_YET_RECRUITING | NCT07565701 |
| Epoetin alga (Epogen)/vadadustat | Other | Phase PHASE3 | Anemia Associated With Chronic Kidney Disease | NOT_YET_RECRUITING | NCT07565701 |
| Epoetin alga (Epogen)/vadadustat | Other | Phase PHASE3 | Anemia Associated With Chronic Kidney Disease | NOT_YET_RECRUITING | NCT07565701 |
| Epoetin alga (Epogen)/vadadustat | Other | Phase PHASE3 | Anemia Associated With Chronic Kidney Disease | NOT_YET_RECRUITING | NCT07565701 |
| Epoetin alga (Epogen)/vadadustat | Other | Phase PHASE3 | Anemia Associated With Chronic Kidney Disease | NOT_YET_RECRUITING | NCT07565701 |
| Epoetin alga (Epogen)/vadadustat | Other | Phase PHASE3 | Anemia Associated With Chronic Kidney Disease | NOT_YET_RECRUITING | NCT07565701 |
| Placebo | Other | Phase PHASE2 | Anemia | COMPLETED | NCT03054350 |
| Vadadustat | Other | Phase PHASE2 | Anemia | COMPLETED | NCT03054350 |
| Placebo | Other | Phase PHASE2 | Anemia | COMPLETED | NCT03054337 |
| Vadadustat | Other | Phase PHASE2 | Anemia | COMPLETED | NCT03054337 |
| Vadadustat | Other | Phase PHASE2 | Chronic Kidney Disease | COMPLETED | NCT04707573 |
| Placebo | Other | Phase PHASE2 | Anemia | COMPLETED | NCT01381094 |
| AKB-6548 | Other | Phase PHASE2 | Anemia | COMPLETED | NCT01381094 |
| AKB-6548 | Other | Phase PHASE2 | Anemia | COMPLETED | NCT01235936 |
| Darbepoetin alfa | Other | Phase PHASE3 | Anemia | WITHDRAWN | NCT03242967 |
| Vadadustat | Other | Phase PHASE3 | Anemia | WITHDRAWN | NCT03242967 |
| AKB-6548 | Other | Phase PHASE1 | Healthy Volunteers | COMPLETED | NCT02502500 |
| Celecoxib | Other | Phase PHASE1 | Healthy Volunteers | COMPLETED | NCT02502500 |
| AKB-6548 tablet, test formulation given in the fed state | Other | Phase PHASE1 | Healthy | COMPLETED | NCT02412449 |
| AKB-6548 tablet, test formulation given in the fasted state. | Other | Phase PHASE1 | Healthy | COMPLETED | NCT02412449 |
| AKB-6548 tablet, reference formulation given in the fasted state | Other | Phase PHASE1 | Healthy | COMPLETED | NCT02412449 |
| Ferrous Sulfate | Other | Phase PHASE1 | Healthy Volunteers | COMPLETED | NCT02327546 |
| AKB-6548 | Other | Phase PHASE1 | Healthy Volunteers | COMPLETED | NCT02327546 |
| Moxifloxacin | Other | Phase PHASE1 | Healthy Volunteers | COMPLETED | NCT02062203 |
| Placebo | Other | Phase PHASE1 | Healthy Volunteers | COMPLETED | NCT02062203 |
| AKB-6548 (supratherapeutic dose) | Other | Phase PHASE1 | Healthy Volunteers | COMPLETED | NCT02062203 |
| AKB-6548 (therapeutic dose) | Other | Phase PHASE1 | Healthy Volunteers | COMPLETED | NCT02062203 |
| Digoxin | Other | Phase PHASE1 | Drug Interaction Potentiation | COMPLETED | NCT03801759 |
| Adefovir | Other | Phase PHASE1 | Drug Interaction Potentiation | COMPLETED | NCT03801759 |
| Furosemide | Other | Phase PHASE1 | Drug Interaction Potentiation | COMPLETED | NCT03801759 |
| Vadadustat | Other | Phase PHASE1 | Drug Interaction Potentiation | COMPLETED | NCT03801759 |
| Cyclosporins | Other | Phase PHASE1 | Drug Interaction Potentiation | COMPLETED | NCT03801746 |
| Probenecid | Other | Phase PHASE1 | Drug Interaction Potentiation | COMPLETED | NCT03801746 |
| Rifampin | Other | Phase PHASE1 | Drug Interaction Potentiation | COMPLETED | NCT03801746 |
| vadadustat | Other | Phase PHASE1 | Drug Interaction Potentiation | COMPLETED | NCT03801746 |
| Sulfasalazine | Other | Phase PHASE1 | Drug Interaction Potentiation | COMPLETED | NCT03801733 |
| Pravastatin | Other | Phase PHASE1 | Drug Interaction Potentiation | COMPLETED | NCT03801733 |
| Atorvastatin | Other | Phase PHASE1 | Drug Interaction Potentiation | COMPLETED | NCT03801733 |
| Rosuvastatin | Other | Phase PHASE1 | Drug Interaction Potentiation | COMPLETED | NCT03801733 |
| Simvastatin | Other | Phase PHASE1 | Drug Interaction Potentiation | COMPLETED | NCT03801733 |
| Vadadustat | Other | Phase PHASE1 | Drug Interaction Potentiation | COMPLETED | NCT03801733 |
| Vadadustat | Other | Phase PHASE1 | Hepatic Impairment | COMPLETED | NCT03799848 |
| Rabeprazole | Other | Phase PHASE1 | Drug Interaction Potentiation | COMPLETED | NCT03789032 |
| Vadadustat | Other | Phase PHASE1 | Drug Interaction Potentiation | COMPLETED | NCT03789032 |
| vadadustat | Other | Phase PHASE1 | Healthy | COMPLETED | NCT03657290 |
| vadadustat test tablets | Other | Phase PHASE1 | Healthy | COMPLETED | NCT03639155 |
| vadadustat reference tablets | Other | Phase PHASE1 | Healthy | COMPLETED | NCT03639155 |
| Epoetin alfa | Other | Phase PHASE1 | Anemia Associated With Chronic Kidney Disease | COMPLETED | NCT03992066 |
| Darbepoetin alfa | Other | Phase PHASE1 | Anemia Associated With Chronic Kidney Disease | COMPLETED | NCT03992066 |
| Vadadustat | Other | Phase PHASE1 | Anemia Associated With Chronic Kidney Disease | COMPLETED | NCT03992066 |
| Auryxia® | Other | Phase PHASE1 | Healthy Volunteers | COMPLETED | NCT04299633 |
| Calcium acetate | Other | Phase PHASE1 | Healthy Volunteers | COMPLETED | NCT04299633 |
| Sevelamer carbonate | Other | Phase PHASE1 | Healthy Volunteers | COMPLETED | NCT04299633 |
| Vadadustat | Other | Phase PHASE1 | Healthy Volunteers | COMPLETED | NCT04299633 |
| epoetin alfa | Other | Phase PHASE2 | Anemia | TERMINATED | NCT03140722 |
| vadadustat | Other | Phase PHASE2 | Anemia | TERMINATED | NCT03140722 |
| Darbepoetin alfa | Other | Phase PHASE3 | Anemia | COMPLETED | NCT02680574 |
| Vadadustat | Other | Phase PHASE3 | Anemia | COMPLETED | NCT02680574 |
| Darbepoetin alfa | Other | Phase PHASE3 | Anemia | COMPLETED | NCT02648347 |
| Vadadustat | Other | Phase PHASE3 | Anemia | COMPLETED | NCT02648347 |
| Darbepoetin alfa | Other | Phase PHASE3 | Anemia | COMPLETED | NCT02892149 |
| Vadadustat | Other | Phase PHASE3 | Anemia | COMPLETED | NCT02892149 |
| AKB-6548 | Other | Phase PHASE2 | Anemia | COMPLETED | NCT02260193 |
| Darbepoetin alfa | Other | Phase PHASE3 | Anemia | COMPLETED | NCT02865850 |
| Vadadustat | Other | Phase PHASE3 | Anemia | COMPLETED | NCT02865850 |
| Placebo | Other | Phase PHASE2 | Anemia | COMPLETED | NCT01906489 |
| AKB-6548 | Other | Phase PHASE2 | Anemia | COMPLETED | NCT01906489 |
| Vadadustat TIW | Other | Phase PHASE2 | Anemia | COMPLETED | NCT03799627 |
| Epoetin Alfa | Other | Phase PHASE2 | Anemia | COMPLETED | NCT03799627 |
| Vadadustat | Other | Phase PHASE2 | Anemia | COMPLETED | NCT03799627 |
| Standard of care phosphate-lowering therapy | Drug | Phase PHASE4 | Hyperphosphatemia | COMPLETED | NCT04922645 |
| Ferric Citrate 1 gram Oral Tablet | Other | Phase PHASE4 | Hyperphosphatemia | COMPLETED | NCT04922645 |
| Mircera® | Other | Phase PHASE3 | Anemia Associated With Chronic Kidney Disease (CKD) | COMPLETED | NCT04707768 |
| Vadadustat | Other | Phase PHASE3 | Anemia Associated With Chronic Kidney Disease (CKD) | COMPLETED | NCT04707768 |
| placebo | Other | Phase PHASE2 | Acute Respiratory Distress Syndrome | COMPLETED | NCT04478071 |
| vadadustat | Other | Phase PHASE2 | Acute Respiratory Distress Syndrome | COMPLETED | NCT04478071 |
| Darbepoetin alfa | Other | Phase PHASE3 | Anemia | COMPLETED | NCT04313153 |
| Vadadustat | Other | Phase PHASE3 | Anemia | COMPLETED | NCT04313153 |
| Placebo | Other | Phase PHASE3 | Anemia, Iron Deficiency | COMPLETED | NCT05085275 |
| Ferric Citrate 1 GM Oral Tablet [AURYXIA] | Other | Phase PHASE3 | Anemia, Iron Deficiency | COMPLETED | NCT05085275 |
| Erythropoiesis Stimulating Agent | Other | Phase PHASE3 | Anemia of Chronic Kidney Disease | ACTIVE_NOT_RECRUITING | NCT06520826 |
| Vadadustat | Other | Phase PHASE3 | Anemia of Chronic Kidney Disease | ACTIVE_NOT_RECRUITING | NCT06520826 |
| Vadadustat | Other | Phase PHASE3 | Anemia of Chronic Kidney Disease | WITHDRAWN | NCT05082584 |
| vadadustat | Other | Phase PHASE3 | Anemia of Chronic Kidney Disease | WITHDRAWN | NCT05082571 |
| Placebo | Other | Phase PHASE2 | Nonintubated Acute Respiratory Distress Syndrome (ARDS) | RECRUITING | NCT07086755 |
| Vadadustat 1200mg | Other | Phase PHASE2 | Nonintubated Acute Respiratory Distress Syndrome (ARDS) | RECRUITING | NCT07086755 |
| Vadadustat 900mg | Other | Phase PHASE2 | Nonintubated Acute Respiratory Distress Syndrome (ARDS) | RECRUITING | NCT07086755 |
| Vadadustat | Other | Phase PHASE3 | Anemia of Chronic Kidney Disease | ACTIVE_NOT_RECRUITING | NCT06901505 |
| Erythropoiesis-Stimulating Agent (ESA) | Other | Phase PHASE3 | Anemia of Chronic Kidney Disease | ACTIVE_NOT_RECRUITING | NCT06901505 |
| Placebo | Other | Phase PHASE1 | Healthy Volunteers | RECRUITING | NCT07429006 |
| AKB-9090 | Other | Phase PHASE1 | Healthy Volunteers | RECRUITING | NCT07429006 |
| Placebo | Other | Phase PHASE2 | Focal Segmental Glomerulosclerosis | RECRUITING | NCT07268638 |
| Praliciguat | Other | Phase PHASE2 | Focal Segmental Glomerulosclerosis | RECRUITING | NCT07268638 |
| Placebo | Other | Phase PHASE2 | Focal Segmental Glomerulosclerosis | RECRUITING | NCT07268638 |
| Praliciguat | Other | Phase PHASE2 | Focal Segmental Glomerulosclerosis | RECRUITING | NCT07268638 |
| Placebo | Other | Phase PHASE2 | Focal Segmental Glomerulosclerosis | RECRUITING | NCT07268638 |
| Praliciguat | Other | Phase PHASE2 | Focal Segmental Glomerulosclerosis | RECRUITING | NCT07268638 |
| Placebo | Other | Phase PHASE2 | Focal Segmental Glomerulosclerosis | RECRUITING | NCT07268638 |
| Praliciguat | Other | Phase PHASE2 | Focal Segmental Glomerulosclerosis | RECRUITING | NCT07268638 |
| Placebo | Other | Phase PHASE2 | Focal Segmental Glomerulosclerosis | RECRUITING | NCT07268638 |
| Praliciguat | Other | Phase PHASE2 | Focal Segmental Glomerulosclerosis | RECRUITING | NCT07268638 |
| Placebo | Other | Phase PHASE2 | Focal Segmental Glomerulosclerosis | RECRUITING | NCT07268638 |
| Praliciguat | Other | Phase PHASE2 | Focal Segmental Glomerulosclerosis | RECRUITING | NCT07268638 |
| Placebo | Other | Phase PHASE2 | Focal Segmental Glomerulosclerosis | RECRUITING | NCT07268638 |
| Praliciguat | Other | Phase PHASE2 | Focal Segmental Glomerulosclerosis | RECRUITING | NCT07268638 |
| Placebo | Other | Phase PHASE2 | Focal Segmental Glomerulosclerosis | RECRUITING | NCT07268638 |
| Praliciguat | Other | Phase PHASE2 | Focal Segmental Glomerulosclerosis | RECRUITING | NCT07268638 |
| Placebo | Other | Phase PHASE2 | Focal Segmental Glomerulosclerosis | RECRUITING | NCT07268638 |
| Praliciguat | Other | Phase PHASE2 | Focal Segmental Glomerulosclerosis | RECRUITING | NCT07268638 |
| Placebo | Other | Phase PHASE2 | Focal Segmental Glomerulosclerosis | RECRUITING | NCT07268638 |
| Praliciguat | Other | Phase PHASE2 | Focal Segmental Glomerulosclerosis | RECRUITING | NCT07268638 |
| Placebo | Other | Phase PHASE2 | Focal Segmental Glomerulosclerosis | RECRUITING | NCT07268638 |
| Praliciguat | Other | Phase PHASE2 | Focal Segmental Glomerulosclerosis | RECRUITING | NCT07268638 |
| Placebo | Other | Phase PHASE2 | Focal Segmental Glomerulosclerosis | RECRUITING | NCT07268638 |
| Praliciguat | Other | Phase PHASE2 | Focal Segmental Glomerulosclerosis | RECRUITING | NCT07268638 |
| AKB-9090 | DRUG | Phase PHASE1 | Healthy Volunteers | NOT_YET_RECRUITING | NCT07429006 |
| Praliciguat | DRUG | Phase PHASE2 | Focal Segmental Glomerulosclerosis | RECRUITING | NCT07268638 |
| Vadadustat 1200mg | DRUG | Phase PHASE2 | Nonintubated Acute Respiratory Distress Syndrome (ARDS) | RECRUITING | NCT07086755 |
| Vadadustat 900mg | DRUG | Phase PHASE2 | Nonintubated Acute Respiratory Distress Syndrome (ARDS) | RECRUITING | NCT07086755 |
| Erythropoiesis-Stimulating Agent (ESA) | DRUG | Phase PHASE3 | Anemia of Chronic Kidney Disease | ACTIVE_NOT_RECRUITING | NCT06901505 |
| Erythropoiesis Stimulating Agent | DRUG | Phase PHASE3 | Anemia of Chronic Kidney Disease | ACTIVE_NOT_RECRUITING | NCT06520826 |
| Ferric Citrate 1 GM Oral Tablet [AURYXIA] | DRUG | Phase PHASE3 | Anemia, Iron Deficiency | COMPLETED | NCT05085275 |
| Standard of care phosphate-lowering therapy | DRUG | Phase PHASE4 | Hyperphosphatemia | COMPLETED | NCT04922645 |
| Ferric Citrate 1 gram Oral Tablet | DRUG | Phase PHASE4 | Hyperphosphatemia | COMPLETED | NCT04922645 |
| Mircera® | DRUG | Phase PHASE3 | Anemia Associated With Chronic Kidney Disease (CKD) | COMPLETED | NCT04707768 |
| placebo | DRUG | Phase PHASE2 | Acute Respiratory Distress Syndrome | COMPLETED | NCT04478071 |
| Auryxia® | DRUG | Phase PHASE1 | Healthy Volunteers | COMPLETED | NCT04299633 |
| Calcium acetate | DRUG | Phase PHASE1 | Healthy Volunteers | COMPLETED | NCT04299633 |
| Sevelamer carbonate | DRUG | Phase PHASE1 | Healthy Volunteers | COMPLETED | NCT04299633 |
| Epoetin alfa | DRUG | Phase PHASE1 | Anemia Associated With Chronic Kidney Disease | COMPLETED | NCT03992066 |
| Digoxin | DRUG | Phase PHASE1 | Drug Interaction Potentiation | COMPLETED | NCT03801759 |
| Adefovir | DRUG | Phase PHASE1 | Drug Interaction Potentiation | COMPLETED | NCT03801759 |
| Furosemide | DRUG | Phase PHASE1 | Drug Interaction Potentiation | COMPLETED | NCT03801759 |
| Cyclosporins | DRUG | Phase PHASE1 | Drug Interaction Potentiation | COMPLETED | NCT03801746 |
| Probenecid | DRUG | Phase PHASE1 | Drug Interaction Potentiation | COMPLETED | NCT03801746 |
| Rifampin | DRUG | Phase PHASE1 | Drug Interaction Potentiation | COMPLETED | NCT03801746 |
| Sulfasalazine | DRUG | Phase PHASE1 | Drug Interaction Potentiation | COMPLETED | NCT03801733 |
| Pravastatin | DRUG | Phase PHASE1 | Drug Interaction Potentiation | COMPLETED | NCT03801733 |
| Atorvastatin | DRUG | Phase PHASE1 | Drug Interaction Potentiation | COMPLETED | NCT03801733 |
| Rosuvastatin | DRUG | Phase PHASE1 | Drug Interaction Potentiation | COMPLETED | NCT03801733 |
| Simvastatin | DRUG | Phase PHASE1 | Drug Interaction Potentiation | COMPLETED | NCT03801733 |
| Vadadustat TIW | DRUG | Phase PHASE2 | Anemia | COMPLETED | NCT03799627 |
| Epoetin Alfa | DRUG | Phase PHASE2 | Anemia | COMPLETED | NCT03799627 |
| Rabeprazole | DRUG | Phase PHASE1 | Drug Interaction Potentiation | COMPLETED | NCT03789032 |
| vadadustat test tablets | DRUG | Phase PHASE1 | Healthy | COMPLETED | NCT03639155 |
| vadadustat reference tablets | DRUG | Phase PHASE1 | Healthy | COMPLETED | NCT03639155 |
| epoetin alfa | DRUG | Phase PHASE2 | Anemia | TERMINATED | NCT03140722 |
| vadadustat | DRUG | Phase PHASE3 | Anemia of Chronic Kidney Disease | WITHDRAWN | NCT05082571 |
| Darbepoetin alfa | DRUG | Phase PHASE3 | Anemia | COMPLETED | NCT04313153 |
| Vadadustat | DRUG | Phase PHASE3 | Anemia of Chronic Kidney Disease | ACTIVE_NOT_RECRUITING | NCT06901505 |
| Celecoxib | DRUG | Phase PHASE1 | Healthy Volunteers | COMPLETED | NCT02502500 |
| AKB-6548 tablet, test formulation given in the fed state | DRUG | Phase PHASE1 | Healthy | COMPLETED | NCT02412449 |
| AKB-6548 tablet, test formulation given in the fasted state. | DRUG | Phase PHASE1 | Healthy | COMPLETED | NCT02412449 |
| AKB-6548 tablet, reference formulation given in the fasted state | DRUG | Phase PHASE1 | Healthy | COMPLETED | NCT02412449 |
| Ferrous Sulfate | DRUG | Phase PHASE1 | Healthy Volunteers | COMPLETED | NCT02327546 |
| Moxifloxacin | DRUG | Phase PHASE1 | Healthy Volunteers | COMPLETED | NCT02062203 |
| AKB-6548 (supratherapeutic dose) | DRUG | Phase PHASE1 | Healthy Volunteers | COMPLETED | NCT02062203 |
| AKB-6548 (therapeutic dose) | DRUG | Phase PHASE1 | Healthy Volunteers | COMPLETED | NCT02062203 |
| Placebo | OTHER | Phase PHASE1 | Healthy Volunteers | NOT_YET_RECRUITING | NCT07429006 |
| AKB-6548 | DRUG | Phase PHASE1 | Healthy Volunteers | COMPLETED | NCT02502500 |
Total products: 173